Carbocisteine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Carbocisteine: From Mucolytic Use to Gout
One-Sentence Summary
Carbocisteine is a mucolytic, used for respiratory disorders marked by thick, viscous mucus. The TxGNN model predicts it may be effective for gout, but no clinical trials and no publications currently support this direction. The prediction rests on the graph model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Mucus-related respiratory disorders (mucolytic). The Singapore registration records do not state an indication text. |
| Predicted New Indication | Gout |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Carbocisteine is a mucolytic that alters mucus viscoelasticity. Laboratory work also suggests antioxidant and anti-inflammatory properties.
No data connect these properties to urate metabolism or to the inflammation seen in gout. The very high TxGNN score is a graph-based prediction only. The link between a respiratory mucolytic and a disorder of uric acid metabolism is therefore not mechanistically supported at present.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
All 7 registrations are valid single-ingredient products. The 5 main ones are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN02852P | SCMC Syrup 100 mg/5 ml | Syrup | Not listed in the registration record |
| SIN10844P | Mucodin Tablet 375 mg | Tablet | Not listed in the registration record |
| SIN02771P | Rhinathiol 2% Children Syrup | Syrup | Not listed in the registration record |
| SIN03003P | Mucodin Syrup 250 mg/5 ml | Syrup | Not listed in the registration record |
| SIN12251P | Solmux Paediatric Suspension 200 mg/5 ml | Suspension | Not listed in the registration record |
Safety Considerations
- Knowledge-graph contraindication signal: The TxGNN knowledge graph (PrimeKG) links carbocisteine to a contraindication in active peptic ulcer disease. This comes from graph data, not from product label text, and should be checked against the package insert.
For other safety information, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The gout prediction has a very high model score, but there are no trials or publications, and no identifiable mechanistic link to urate metabolism or gouty inflammation. The evidence is at the lowest level (L5), so there is no basis to advance it.
To proceed, the following is needed:
- Mechanistic data showing a plausible effect on uric acid handling or gouty inflammation, for example in preclinical models
- Detailed mechanism of action data for carbocisteine
- Package insert warnings and contraindications from the Singapore regulator, to complete safety screening
- Confirmation of approved indications for the registered Singapore products
Note: Among the other predictions, bronchitis (score 98.77%) has more supporting evidence, at L3. It includes a long-term double-blind placebo-controlled trial (1985) and a 2024 systematic review of mucolytics in stable COPD. It is closer to an on-label use than a true repurposing, and it is the more practical direction to evaluate.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.